¹Ì±¹ÀÇ Á¦³×¸¯ ÁÖ»çÁ¦ ¼öŹÁ¦Á¶ ½ÃÀå ±Ô¸ð, Á¡À¯À² ¹× µ¿Ç⠺м® º¸°í¼ : ºÐÀÚº°, ¿ëµµº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)
U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market Size, Share & Trends Analysis Report By Molecule, By Application, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå
:
1588383
¸®¼Ä¡»ç
:
Grand View Research, Inc.
¹ßÇàÀÏ
:
2024³â 10¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 140 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¹Ì±¹ÀÇ Á¦³×¸¯ ÁÖ»çÁ¦ ¼öŹÁ¦Á¶ ½ÃÀå ¼ºÀå ¹× µ¿Çâ :
Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼¿¡ µû¸£¸é, ¹Ì±¹ÀÇ Á¦³×¸¯ ÁÖ»çÁ¦ ¼öŹÁ¦Á¶ ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 55¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¹Ì±¹ ½ÃÀåÀº 2025³âºÎÅÍ 2030³â±îÁö ¿¬Æò±Õ 10.8%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ºí·Ï¹ö½ºÅÍ ÀǾàǰÀÇ Æ¯Çã ¸¸·á ºóµµ Áõ°¡, ±ÔÁ¦ °æ·ÎÀÇ °£¼ÒÈ, Á¦³×¸¯ ÀǾàǰÀÇ Àúºñ¿ëÈ, Á¦³×¸¯ ÁÖ»çÁ¦ ºÐ¾ß¿¡¼ CDMOÀÇ º¸±Þ È®´ëÀÔ´Ï´Ù.
Äڷγª19 ÆÒµ¥¹ÍÀº ¹Ì±¹ÀÇ Á¦³×¸¯ ÁÖ»çÁ¦ ¼öŹÁ¦Á¶ ºÎ¹®À» Æ÷ÇÔÇÑ °ø±Þ¸Á ½ÃÀå°ú ±× °ü¸®¿¡ Å« ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. »õ·Î¿î Á¦³×¸¯ ÁÖ»çÁ¦ÀÇ ÀÓ»ó½ÃÇè ½Ç½Ã´Â Àü¿°º´°ú °ü·ÃµÈ ¾ÈÀü ¿ì·Á ¹× Á¦ÇÑÀ¸·Î ÀÎÇØ º¯°æµÇ°Å³ª ¿¬±âµÇ¾î °³¹ß ÀÏÁ¤¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿©·¯ Á¦¾àȸ»ç°¡ Äڷγª19 ¹é½Å »ý»ê¿¡ »ý»ê´É·ÂÀ» ÅõÀÔÇÏ¸é¼ Á¦³×¸¯ ÁÖ»çÁ¦¸¦ Æ÷ÇÔÇÑ ´Ù¸¥ ÀǾàǰÀÇ »ý»ê ÀÏÁ¤°ú »ý»ê´É·Â¿¡ Å« ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù.
»ý¹°ÇÐÀû Á¦Á¦ ÁÖ»çÁ¦ÀÇ Æ¯Çã°¡ ¸¸·áµÇ´Â ÁÖ»çÁ¦ÀÇ ¼ö°¡ Áõ°¡Çϰí ÀÖ´Â °ÍÀº ¹Ì±¹ Á¦³×¸¯ ÁÖ»çÁ¦ ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©ÇÏ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, ¹Ì±¹ FDA¿¡ µû¸£¸é Å©·Ðº´, °üÀý¿°, ½É»ó¼º °Ç¼±, °Á÷¼º ôÃß¿°À» Ä¡·áÇÏ´Â ¾Öºêºñ(AbbVie)ÀÇ È÷Æ® ÁÖ»çÁ¦ È޹̶ó(Humira)´Â 2023³â ƯÇã°¡ ¸¸·áµË´Ï´Ù. ƯÇã ¸¸·á·Î ÀÎÇØ ¾Æ´Þ¸®¹«¸¿ÀÇ Á¦³×¸¯ ÀǾàǰ µµÀÔÀÇ ±æÀÌ ¿·È½À´Ï´Ù. ºñ¿ë È¿À²¼ºÀ¸·Î ÀÎÇØ Á¦³×¸¯ ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ´Â °Íµµ ¹Ì±¹ÀÇ Á¦³×¸¯ ÁÖ»çÁ¦ ¼öŹÁ¦Á¶ ½ÃÀåÀÇ ¼ºÀå¿¡ Å« ±â¿©¸¦ Çϰí ÀÖ½À´Ï´Ù.
¹Ì±¹ÀÇ Á¦³×¸¯ ÁÖ»çÁ¦ ¼öŹÁ¦Á¶ ½ÃÀå º¸°í¼ - ÁÖ¿ä ³»¿ë
- ºÐÀÚ ºÎ¹®º°·Î ½ÃÀåÀº ÀúºÐÀÚ¿Í °íºÐÀÚ·Î ºÐ·ùµÇ¸ç, 2024³â¿¡´Â °íºÐÀÚ ºÎ¹®ÀÌ 58.02%ÀÇ ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇÏ¸ç ½ÃÀåÀ» Àå¾ÇÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
- ÀúºÐÀÚ ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È 10.40%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀúºÐÀÚ ±â¹Ý ÁÖ»çÁ¦´Â ¾Ï, Ç÷¾× Áúȯ, °¨¿°¼º Áúȯ, ½ÉÇ÷°ü Áúȯ µî ´Ù¾çÇÑ ÁúȯÀÇ Ä¡·á¿¡ ÀÖ¾î Áß¿äÇÑ À§Ä¡¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.
- ¿ëµµº°·Î ½ÃÀåÀº ¾Ï, ¸é¿ª, Ç×´ç´¢º´, ½Å°æ, ¼øÈ¯±â, È£Èí±â, ±âŸ·Î ºÐ·ùµÇ¸ç, 2024³â¿¡´Â ¾Ï ºÐ¾ß°¡ 29.42%ÀÇ ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇÏ¸ç ½ÃÀåÀ» Àå¾ÇÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
- ½Å°æ ºÐ¾ß´Â ¿¹Ãø ±â°£ µ¿¾È 11.64%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå ¹Ì±¹ÀÇ Á¦³×¸¯ ÁÖ»çÁ¦ ¼öŹÁ¦Á¶ ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§
- ½ÃÀå °èÅë Àü¸Á
- »óÀ§ ½ÃÀå Àü¸Á
- °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
- ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
- ¹Ì±¹ÀÇ Á¦³×¸¯ ÁÖ»çÁ¦ ¼öŹÁ¦Á¶ ½ÃÀå ºÐ¼® Åø
- ¾÷°è ºÐ¼® - PorterÀÇ Five Forces ºÐ¼®
- PESTEL ºÐ¼®
- COVID-19ÀÇ ¿µÇ⠺м®
Á¦4Àå ¹Ì±¹ÀÇ Á¦³×¸¯ ÁÖ»çÁ¦ ¼öŹÁ¦Á¶ ½ÃÀå : ºÐÀÚ ÃßÁ¤¡¤µ¿Ç⠺м®
- ¹Ì±¹ÀÇ Á¦³×¸¯ ÁÖ»çÁ¦ ¼öŹÁ¦Á¶ ½ÃÀå, ºÐÀÚº° : ºÎ¹® ´ë½Ãº¸µå
- ¹Ì±¹ÀÇ Á¦³×¸¯ ÁÖ»çÁ¦ ¼öŹÁ¦Á¶ ½ÃÀå, ºÐÀÚº° : º¯µ¿ ºÐ¼®
- ºÐÀÚ, 2018³â-2030³â
Á¦5Àå ¹Ì±¹ÀÇ Á¦³×¸¯ ÁÖ»çÁ¦ ¼öŹÁ¦Á¶ ½ÃÀå : ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®
- ¹Ì±¹ÀÇ Á¦³×¸¯ ÁÖ»çÁ¦ ¼öŹÁ¦Á¶ ½ÃÀå, ¿ëµµº° : ºÎ¹® ´ë½Ãº¸µå
- ¹Ì±¹ÀÇ Á¦³×¸¯ ÁÖ»çÁ¦ ¼öŹÁ¦Á¶ ½ÃÀå, ¿ëµµº° : º¯µ¿ ºÐ¼®
- ¿ëµµº°, 2018³â-2030³â
- Á¾¾çÇÐ
- ¸é¿ªÇÐ
- Ç×´ç´¢º´Á¦
- ½Å°æÇÐ
- ½ÉÀåÇ÷°ü
- È£Èí±â
- ±âŸ
Á¦6Àå °æÀï ±¸µµ
- ½ÃÀå ÁøÃâ±â¾÷ ºÐ·ù
- Çõ½Å±â¾÷
- ½ÃÀå ¸®´õ
- ½ÅÈï ±â¾÷
- ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®, 2024³â
- ±â¾÷ °³¿ä
- Charles River Laboratories International, Inc.
- Hikma Pharmaceuticals PLC
- Pfizer Inc.
- Fresenius Kabi
- Sandoz AG
- Jubilant Pharma Limited
- Baxter
- PCI Pharma Services.
- Gland Pharma Limited(USA)
- Dr.Reddy's Laboratories Ltd.
- Grand River Aseptic Manufacturing
LSH
¿µ¹® ¸ñÂ÷
U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market Growth & Trends:
The U.S. generic injectables pharmaceutical contract manufacturing market size is expected to reach USD 5.59 billion by 2030, according to a new report by Grand View Research, Inc. The U.S. market is expected to expand at a CAGR of 10.8% from 2025 to 2030. Key factors driving the growth of this market are the rising frequency of patent expirations for blockbuster drugs, streamlined regulatory pathways, low cost of generics, and increasing penetration of CDMOs in the generic injectables space.
The COVID-19 pandemic significantly impacted the supply chain market and its management, including the U.S. generic injectables pharmaceutical contract manufacturing sector. The conduction of clinical trials for new generic injectables has been modified or delayed due to pandemic-related safety concerns and restrictions, potentially impacting the development timeline. Furthermore, several pharmaceutical companies pivoted their production capacities to manufacture COVID-19 vaccines, significantly impacting the production timelines and capacity for other pharmaceuticals, including generic injectables.
The increasing number of patent expirations for biologic injectables is a key factor contributing to the growth of the generic injectables market in the country. For instance, as per the U.S. FDA, the blockbuster injectable drug Humira, developed by AbbVie Inc. that treats the symptoms of Crohn's disease, arthritis, plaque psoriasis, and Ankylosing Spondylitis, has lost its patent in 2023. This expiration has paved the way for introducing its generic counterpart, adalimumab. The rising demand for generics owing to their cost-effectiveness is another significant factor contributing to the growth of the U.S. market for generic injectables pharmaceutical contract manufacturing.
U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market Report Highlights:
- On the basis of molecule segment, the market is segregated into small molecule, and large molecule. In 2024, the large molecule segment dominated the market, accounting for a revenue share of 58.02%.
- The small molecule segment is anticipated to register the CAGR of 10.40% during the forecast period. Small molecule-based injectable drugs continue to hold an essential position in the treatment of a wide range of illnesses, including cancer, blood disorders, infectious diseases, and cardiovascular ailments.
- On the basis of application segment, the market is segregated into oncology, immunology, antidiabetic, neurology, cardiovascular, respiratory, and others. In 2024, the oncology segment dominated the market, accounting for a revenue share of 29.42%.
- The neurology segment is anticipated to register the fastest CAGR of 11.64% during the forecast period.
Table of Contents
Chapter 1. Research Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Molecule
- 1.2.2. Application
- 1.3. Regional Scope
- 1.4. Estimates And Forecast Timeline
- 1.5. Research Methodology
- 1.6. Information Procurement
- 1.6.1. Purchased Database
- 1.6.2. GVR's Internal Database
- 1.6.3. Secondary Sources
- 1.6.4. Primary Research
- 1.7. Information Or Data Analysis
- 1.7.1. Data Analysis Models
- 1.8. Market Formulation & Validation
- 1.9. Model Details
- 1.9.1. Commodity Flow Analysis
- 1.9.2. Parent Market Analysis
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Rising frequency of patent expirations for blockbuster drugs
- 3.2.1.2. Streamlined regulatory pathway and low cost of generics
- 3.2.1.3. Increasing penetration of CDMOs in the generic injectables space
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. Presence of substitute therapies
- 3.2.2.2. Compliance issues while outsourcing
- 3.3. U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.2. PESTEL Analysis
- 3.3.3. COVID-19 Impact Analysis
Chapter 4. U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market: Molecule Estimates & Trend Analysis
- 4.1. U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market, By Molecule: Segment Dashboard
- 4.2. U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market, By Molecule: Movement Analysis
- 4.3. U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Molecule, 2018 - 2030
- 4.3.1. Small Molecule
- 4.3.1.1. Small Molecule Market, 2018 to 2030 (USD Million)
- 4.3.2. Large Molecule
- 4.3.2.1. Large Molecule Market, 2018 to 2030 (USD Million)
Chapter 5. U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market: Application Estimates & Trend Analysis
- 5.1. U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market, By Application: Segment Dashboard
- 5.2. U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market, By Application: Movement Analysis
- 5.3. U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Application, 2018 - 2030
- 5.3.1. Oncology
- 5.3.1.1. Oncology Market, 2018 to 2030 (USD Million)
- 5.3.2. Immunology
- 5.3.2.1. Immunology Market, 2018 to 2030 (USD Million)
- 5.3.3. Antidiabetic
- 5.3.3.1. Antidiabetic Market, 2018 to 2030 (USD Million)
- 5.3.4. Neurology
- 5.3.4.1. Neurology Market, 2018 to 2030 (USD Million)
- 5.3.5. Cardiovascular
- 5.3.5.1. Cardiovascular Market, 2018 to 2030 (USD Million)
- 5.3.6. Respiratory
- 5.3.6.1. Respiratory Market, 2018 to 2030 (USD Million)
- 5.3.7. Others
- 5.3.7.1. Others Market, 2018 to 2030 (USD Million)
Chapter 6. Competitive Landscape
- 6.1. Market Participant Categorization
- 6.1.1. Innovators
- 6.1.2. Market Leaders
- 6.1.3. Emerging Players
- 6.1.4. Company Market Share Analysis, 2024
- 6.2. Company Profiles
- 6.2.1. Charles River Laboratories International, Inc.
- 6.2.1.1. Company Overview
- 6.2.1.2. Financial Performance
- 6.2.1.3. Service Benchmarking
- 6.2.1.4. Strategic Initiatives
- 6.2.2. Hikma Pharmaceuticals PLC
- 6.2.2.1. Company Overview
- 6.2.2.2. Financial Performance
- 6.2.2.3. Service Benchmarking
- 6.2.2.4. Strategic Initiatives
- 6.2.3. Pfizer Inc.
- 6.2.3.1. Company Overview
- 6.2.3.2. Financial Performance
- 6.2.3.3. Service Benchmarking
- 6.2.3.4. Strategic Initiatives
- 6.2.4. Fresenius Kabi
- 6.2.4.1. Company Overview
- 6.2.4.2. Financial Performance
- 6.2.4.3. Service Benchmarking
- 6.2.4.4. Strategic Initiatives
- 6.2.5. Sandoz AG
- 6.2.5.1. Company Overview
- 6.2.5.2. Financial Performance
- 6.2.5.3. Service Benchmarking
- 6.2.5.4. Strategic Initiatives
- 6.2.6. Jubilant Pharma Limited
- 6.2.6.1. Company Overview
- 6.2.6.2. Financial Performance
- 6.2.6.3. Service Benchmarking
- 6.2.6.4. Strategic Initiatives
- 6.2.7. Baxter
- 6.2.7.1. Company Overview
- 6.2.7.2. Financial Performance
- 6.2.7.3. Service Benchmarking
- 6.2.7.4. Strategic Initiatives
- 6.2.8. PCI Pharma Services.
- 6.2.8.1. Company Overview
- 6.2.8.2. Financial Performance
- 6.2.8.3. Service Benchmarking
- 6.2.8.4. Strategic Initiatives
- 6.2.9. Gland Pharma Limited (USA)
- 6.2.9.1. Company Overview
- 6.2.9.2. Financial Performance
- 6.2.9.3. Service Benchmarking
- 6.2.9.4. Strategic Initiatives
- 6.2.10. Dr.Reddy's Laboratories Ltd.
- 6.2.10.1. Company Overview
- 6.2.10.2. Financial Performance
- 6.2.10.3. Service Benchmarking
- 6.2.10.4. Strategic Initiatives
- 6.2.11. Grand River Aseptic Manufacturing
- 6.2.11.1. Company Overview
- 6.2.11.2. Financial Performance
- 6.2.11.3. Service Benchmarking
- 6.2.11.4. Strategic Initiatives
°ü·ÃÀÚ·á